ENGN
insider transactionsenGene Therapeutics Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-43.7K
0 buy · 43.7K sell
Net value · 365d
-$143.6K
$0 in · $143.6K out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
2
0 buy · 43.7K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
31.0K sh
Own New
-
Grant·A
Director
$0
31.0K sh
Own New
-
Grant·A
Interim Chief Medical Officer
$0
200.0K sh
Own New
-
Grant·A
Interim Chief Medical Officer
$0
31.0K sh
Own New
-
Grant·A
Director
$0
31.0K sh
Own New
-
Grant·A
Director
$0
31.0K sh
Own New
-
Grant·A
Director
$0
31.0K sh
Own New
-
Sell·S
Director
$89.7K
17.7K sh · $5.08
Own -1%
-
Grant·A
Director
$0
75.0K sh
Own New
-
Grant·A
Director
$0
50.0K sh
Own +4%
-
Other·G
Director
$0
25.0K sh
Own -2%
-
Other·D
Director
—
6.0K sh
Own -100%
-
Other·D
Director
—
2.5K sh
Own -100%
-
Other·D
Director
—
1.9K sh
Own -100%
-
Other·D
Director
—
3.0K sh
Own -100%
-
Other·U
Director
—
950 sh
-
Grant·A
Chief Strategy & Ops. Ofc
$0
195.0K sh
Own New
-
Grant·A
Chief Legal Ofc. and Corp Secy
$0
195.0K sh
Own New
-
Grant·A
Ryan D. Daws KEY
Chief Financial Officer
$0
220.0K sh
Own New
-
Grant·A
Ronald Harold Wilfred Cooper KEY
CEO & President
$0
801.0K sh
Own New
-
Grant·A
Chief Technology Officer
$0
195.0K sh
Own New
-
Grant·A
Chief Scientific Officer
$0
195.0K sh
Own New
-
Grant·A
Chief Development Officer
$0
195.0K sh
Own New
-
Grant·A
Chief Regulatory Officer
$0
195.0K sh
Own New
-
Sell·S
Paul J Hastings KEY
Chief Executive Officer
$53.9K
26.0K sh · $2.07
Own -6%
-
Grant·A
Paul J Hastings KEY
Chief Executive Officer
$0
562.0K sh
Own New
-
Grant·A
Paul J Hastings KEY
Chief Executive Officer
$0
94.0K sh
Own +29%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 16, 2026 | Lota S. Zoth | Grant A | 31.0K | $0 |
| Jun 16, 2026 | Paul J Hastings | Grant A | 31.0K | $0 |
| Jun 16, 2026 | William Grossman | Grant A | 200.0K | $0 |
| Jun 16, 2026 | William Grossman | Grant A | 31.0K | $0 |
| Jun 16, 2026 | Richard M Glickman | Grant A | 31.0K | $0 |
| Jun 16, 2026 | Gerald A Brunk | Grant A | 31.0K | $0 |
| Jun 16, 2026 | Philip Astley-Sparke | Grant A | 31.0K | $0 |
| May 18, 2026 | Philip Astley-Sparke | Sell S | 17.7K | $89.7K |
| Apr 1, 2026 | Philip Astley-Sparke | Grant A | 75.0K | $0 |
| Apr 1, 2026 | Philip Astley-Sparke | Grant A | 50.0K | $0 |
| Feb 18, 2026 | Philip Astley-Sparke | Other G | 25.0K | $0 |
| Feb 9, 2026 | Ronald Harold Wilfred Cooper | Other D | 6.0K | — |
| Feb 9, 2026 | Ronald Harold Wilfred Cooper | Other D | 2.5K | — |
| Feb 9, 2026 | Ronald Harold Wilfred Cooper | Other D | 1.9K | — |
| Feb 9, 2026 | Ronald Harold Wilfred Cooper | Other D | 3.0K | — |
| Feb 9, 2026 | Ronald Harold Wilfred Cooper | Other U | 950 | — |
| Jan 30, 2026 | Alexander Julian Nichols | Grant A | 195.0K | $0 |
| Jan 30, 2026 | Lee Giguere | Grant A | 195.0K | $0 |
| Jan 30, 2026 | Ryan D. Daws KEY | Grant A | 220.0K | $0 |
| Jan 30, 2026 | Ronald Harold Wilfred Cooper KEY | Grant A | 801.0K | $0 |
| Jan 30, 2026 | Joan Connolly | Grant A | 195.0K | $0 |
| Jan 30, 2026 | Anthony Tzeyew Cheung | Grant A | 195.0K | $0 |
| Jan 30, 2026 | Jill Buck | Grant A | 195.0K | $0 |
| Jan 30, 2026 | Matthew Ross Boyd | Grant A | 195.0K | $0 |
| Jan 15, 2026 | Paul J Hastings KEY | Sell S | 26.0K | $53.9K |
| Jan 6, 2026 | Paul J Hastings KEY | Grant A | 562.0K | $0 |
| Jan 6, 2026 | Paul J Hastings KEY | Grant A | 94.0K | $0 |
About ENGN insider trading
This page tracks insider transactions for enGene Therapeutics Inc. (ENGN) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.